[23] WellsS, GosnellJ, GagelR, [J].JClinOncol,2010, 28:767-772.
[24] BrassardM, NeraudB, TrabadoS, [J].JClinEndocrinolMetab,2011, 96（9）:2741-2749.
[25] CarrL, MankoffD, GoulartB, etal.PhaseⅡ studyofdailysunitinibinFDG-PET-positive, iodine-refractorydifferentiatedthyroidcancerandmetastaticmedullarycarcinomaofthethyroidwithfunctionalimagingcorrelation[J].ClinCancerRes, 2010, 16（21）: 5260-5268.
[26] BikasA, KundraP, DesaleS, etal.Phase2clinicaltrialofsunitinibasadjunctivetreatmentinpatientswithadvanceddifferentiatedthyroidcancer[J].EurJEndocrinol,2016, 174:373-380.
[27] RavaudA, FouchardièreC, CaronP, etal.AmulticenterphaseⅡstudyofsunitinibinpatientswithlocallyadvancedormetastaticdifferentiated, anaplasticormedullarythyroidcarcinomas: maturedatafromtheTHYSUstudy[J].EurJCancer,2017 , 76:110-117.
[28] BibleK, SumanV, MolinaJ, , radioiodine-refractory, metastaticdifferentiatedThyroidcancers:resultsofaphase2consortiumstudy[J].LancetOncol,2010, 11（10）:962-972.
[29] BibleK, SumanV, MolinaJ, etal.Amulticenterphase2trialofpazopanibinmetastaticandprogressivemedullarythyroidcarcinoma:MC057H[J].JClinEndocrinolMetab,2014,99（5）:1687-1693.
[30] BibleK, SumanV, MenefeeM, etal.AmultiinStitutionalPhase2trialofpazopanibmonotherapyinadvancedanaplasticthyroidcancer[J].JClinEndocrinolMetab, 2012,97（9）:3179-3184.
哦豁，小伙伴们如果觉得倾城文选不错，记得收藏网址 或推荐给朋友哦~拜托啦 (>.<)
传送门：